In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (HIMS 6.96%) may finally be succeeding in cracking the code.
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
One of the most exciting growth stories in the market is that of Hims & Hers Health Inc. NYSE: HIMS. This company has combined the growth and efficiency aspects of the technology sector with the safety and stability of the medical sector.
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
American telehealth company Hims & Hers Health announced on Tuesday that it will be acquiring Zava, a leading European digital health company in an all cash acquisition set to close in the second half of 2025. Following the announcement, Hims' stock price (HIMS) jumped 5.8% in premarket trading.
Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform.
Hims & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed.
CNBC's Brandon Gomez reports on the latest news regarding Hims.